他汀类药物使用、遗传变异与前列腺癌风险之间的关联
研究基于加拿大多伦多大学健康网络1996—2014年前列腺穿刺活检数据库的3481例患者,采用病例对照设计分析他汀使用与总体及高级别前列腺癌风险,并采用病例-only设计探索候选SNP与GWAS SNP同他汀-癌症关联的交互作用。
要点
- 3481例患者中1104例(32%)活检时使用他汀,2061例(59%)诊断为前列腺癌,其中922例(45%)为高级别。
- 调整基线特征后,他汀使用与总体或高级别前列腺癌风险降低均无关。
核心结论
- 本研究中他汀使用与前列腺癌或高级别前列腺癌风险均无关,研究结果不支持他汀具有前列腺癌化学预防作用。
- 影响他汀代谢的一个候选SNP可能与他汀使用者较低的癌症风险相关,值得进一步研究,但该SNP及其他SNP均未达到全基因组显著性。
研究设计与样本
- 临床与胚系数据提取自加拿大多伦多大学健康网络前列腺穿刺活检数据库(1996—2014年)。
- 采用病例对照设计分析他汀使用与总体及高级别(Grade Group ≥2)前列腺癌风险的关联。
- 采用病例-only设计探索候选SNP与GWAS SNP同他汀-癌症关联的交互作用。
- 共纳入3481例患者,其中1104例(32%)活检时使用他汀。
主要发现
- 他汀使用者年龄更大、体重指数更高、阳性穿刺针数更多、Gleason评分更高。
- 2061例参与者(59%)诊断为前列腺癌,其中922例(45%)为高级别。
- 调整基线特征后,他汀使用与总体或高级别前列腺癌风险降低均无关。
- 两个与他汀代谢相关的独特SNP显示与他汀-癌症关联存在显著交互作用。
关键数值与推荐
- 高级别前列腺癌定义为Grade Group ≥2。
- 无SNP达到全基因组显著性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The association between statin medication use and prostate cancer remains inconclusive. Evidence shows that genetic variation modifies lipid-lowering efficacy of statins, however, there are limited data on the pharmacogenomics of statins in prostate cancer chemoprevention. METHODS: Clinical and germline data were extracted from the prostate biopsy database at the University Health Network, Toronto, Canada (1996-2014). A genome-wide association study (GWAS) and a custom array of 54 single nucleotide polymorphisms (SNPs) related to statin metabolism were performed. Using a case-control design, we examined the associations between statin use and overall and high-grade (Grade Group ≥2) prostate cancer risk. A case-only design was employed to explore interactions between candidate/GWAS SNPs and the statin-cancer association. RESULTS: Among 3481 patients, 1104 (32%) were using statins at biopsy. Statin users were older and had higher body mass index, greater number of positive cores, and higher Gleason scores. In total, 2061 participants (59%) were diagnosed with prostate cancer, with 922 cases (45%) classified as high-grade. When adjusted for baseline characteristics, the use of statins was not associated with decreased risk of overall or high-grade prostate cancer. Two unique SNPs implicated in statin metabolism showed significant interaction with the statin-cancer association. In particular, statin users harboring the GG genotype (n = 668; 24%) of rs10276036 had significantly lower prostate cancer risk (HR 0.71, 95% CI 051-1.00). However, none of the SNPs achieved genome-wide significance. CONCLUSIONS: In our study, statin use was not associated with either prostate cancer or high-grade prostate cancer risk. While one candidate SNP that influences statin metabolism may be associated with a lower cancer risk among statin users and thus warrants further study, neither this nor any other SNPs achieved genome-wide significance. Thus, our findings do not add evidence in support of a prostate cancer chemopreventive role for statins.
引用
- Amiri A, Xu W, Zhang Q, et al. The association between statin use, genetic variation, and prostate cancer risk. Prostate Cancer Prostatic Dis. 2025. PMID: 40195554. doi:10.1038/s41391-025-00964-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。